Peptide finder

What are you trying to change?

Pick as many as you like. The number on each one is how many people it has been measured in across the whole archive. So you can see where the evidence is before you choose.

1. 01TirzepatidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 9 completed trials, 22,802 people given it.11 reported

   6,026 people4 studies

   • It worked, and the dose mattered. Around 2,500 adults with obesity and no diabetes took a weekly tirzepatide shot at one of three strengths, or a dummy shot, for about seventeen months. The dummy group finished about 3% lighter. On tirzepatide people finished 15%, 20% or 21% lighter, rising with the dose. Everyone...

     New England Journal of Medicine, 2022 · 2,539 people

   • Tirzepatide beat semaglutide head to head on blood sugar. Nearly 1,900 people with type 2 diabetes took one drug or the other for about nine months. Every tirzepatide dose brought average blood sugar down further than semaglutide did. People on the strongest tirzepatide dose also lost up to 5.5 kg more, which is about...

     New England Journal of Medicine, 2021 · 1,879 people

   • Tirzepatide produced large weight loss in people who also had type 2 diabetes. 938 adults took the weekly shot or a dummy one for 72 weeks, and nobody involved knew which. Those on the drug lost about 12.8% of their body weight at the middle dose and 14.7% at the top dose. The dummy group lost 3.2%. Around eight in...

     The Lancet, 2023 · 938 people

2. 02SemaglutidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 12 completed trials, 42,363 people given it.10 reported

   5,688 people5 studies

   • It worked, and this is the trial that made semaglutide famous for weight loss. Nearly two thousand adults without diabetes took a weekly shot of either semaglutide or a dummy version for about sixteen months. Nobody involved knew which. The semaglutide group finished roughly 15% lighter. The dummy group finished...

     New England Journal of Medicine, 2021 · 1,961 people

   • A bigger weekly dose took off a little more weight, and cost more side effects. Just over 1,400 adults with obesity took semaglutide at 7.2 mg, semaglutide at the usual 2.4 mg, or a dummy injection for about seventeen months. The high dose group finished roughly 19% lighter, the usual dose roughly 16% lighter, and the...

     The Lancet Diabetes & Endocrinology, 2025 · 1,407 people

   • Semaglutide still worked when people also had diabetes, though the weight loss was smaller. About 1,200 adults with extra weight and type 2 diabetes got the weekly shot or a dummy one, and nobody involved knew which. After 68 weeks the drug group had lost about a tenth of their body weight and the dummy group about...

     The Lancet, 2021 · 1,210 people

3. 03CagriSemaPeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 3 completed trials, 4,954 people given it.8 reported

   4,623 people2 studies

   • This is about as strong as obesity evidence gets. 3,417 adults took the combination or a dummy injection for about 16 months. On the drug they lost roughly a fifth of their body weight. On the dummy they lost about 3 percent. In plain terms, someone starting at 220 pounds ended up around 45 pounds lighter. A second...

     New England Journal of Medicine, 2025 · 3,417 people

   • The same combination worked in people who also had type 2 diabetes, and it worked less well. 1,206 patients took it or a dummy for about 16 months. They lost close to 14 percent of their weight, against roughly 3 percent on the dummy. Weight drugs reliably do less in diabetes than outside it, and this is that pattern...

     New England Journal of Medicine, 2025 · 1,206 people

4. 04LiraglutidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 6 completed trials, 16,760 people given it.9 reported

   4,577 people2 studies

   • Liraglutide at the obesity dose took off real weight, though less than the headlines suggest. 3,731 adults without diabetes took the 3.0 mg shot or a dummy shot for just over a year. Average weight loss was 8.4 kg on the drug and 2.8 kg on the dummy, so about 5.6 kg of it came from the drug. Roughly two thirds lost at...

     New England Journal of Medicine, 2015 · 3,731 people

   • Liraglutide took off a modest amount of weight in people with type 2 diabetes. 846 adults took the daily shot at one of two doses or a dummy one for 56 weeks. Nobody involved knew which. The higher dose took off 6.0% of body weight, the lower dose 4.7%, and the dummy 2.0%. A quarter of the people on the higher dose...

     JAMA, 2015 · 846 people

5. 05Retatrutide with cagrilintideBlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 4 completed trials, 4,557 people given it.6 reported

   3,755 people2 studies

   • A properly developed amylin and gut hormone pairing does exist. It has been tested in a very large study, and it is not this one. 3,417 people took cagrilintide with semaglutide, mixed by the maker, or a dummy shot. After about 16 months average weight was down 20.4%, against 3.0% on the dummy. That is a gap of more...

     New England Journal of Medicine, 2025 · 3,417 people

   • Retatrutide caused very large weight loss, in an early, fairly small study. 338 adults with obesity took a weekly shot at one of four strengths, or a dummy shot, for 11 months. Average weight fell 8.7% at the lowest dose and 24.2% at the highest, against 2.1% on the dummy. At the top dose more than four in five lost...

     New England Journal of Medicine, 2023 · 338 people

6. 06OrforglipronSmall moleculeStrong. At least two finished studies in people, and at least 1,000 people who took it. 8 completed trials, 17,383 people given it.8 reported

   5,116 people5 studies

   • The large trial agreed with the small one, though the average loss came out lower. Over three thousand adults took the highest dose of the tablet or a dummy tablet for about seventeen months. Those on the drug lost 11.2 percent of their weight on average, against 2.1 percent on the dummy. More than a third lost at...

     New England Journal of Medicine, 2025 · 3,127 people

   • A pill in this drug class produced real weight loss in people with both obesity and type 2 diabetes. 1,613 adults took one of three doses or a dummy pill for about seventeen months. Weight fell by roughly 5, 7 and 10 percent as the dose rose, against about 2 percent on the dummy. More people quit for side effects on...

     The Lancet, 2026 · 1,613 people

   • Switching from an injection to this pill held most of the lost weight off, though not all. 376 people who had lost weight on tirzepatide or semaglutide were sorted by chance onto orforglipron or a dummy pill for a year. Among those who had already levelled off, the pill held about three quarters of what they had lost....

     Nature Medicine, 2026 · 376 people

7. 07Semaglutide with cagrilintideBlendStrong. At least two finished studies in people, and at least 1,000 people who took it. 4 completed trials, 4,219 people given it.6 reported

   3,417 people2 studies

   • This is the pair itself, tested as a pair, and it worked. 3,417 people were put by chance on cagrilintide with semaglutide, on either drug alone, or on a dummy shot. After about 16 months average weight was down 20.4% on the pair, against 3.0% on the dummy. That is a gap of more than 17 points. Stomach and bowel side...

     New England Journal of Medicine, 2025 · 3,417 people

   • Semaglutide by itself takes off close to a seventh of body weight. That is the bar the pair has to clear. Adults took a weekly 2.4 mg shot or a dummy shot for about 16 months. Average weight fell 14.9% on the drug, against 2.4% on the dummy. This is semaglutide alone, not the pair. Any claim for adding cagrilintide...

     New England Journal of Medicine, 2021 · number of people not given

8. 08MazdutidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 2,372 people given it.7 reported

   2,052 people4 studies

   • Head to head against an established diabetes drug, mazdutide won on both blood sugar and weight. Seven hundred and thirty-one Chinese adults with type 2 diabetes were given mazdutide at one of two doses or dulaglutide for about seven months. Both mazdutide doses lowered average blood sugar more than dulaglutide did....

     Nature, 2026 · 731 people

   • Mazdutide caused substantial weight loss in a large late stage trial. Six hundred and ten Chinese adults carrying extra weight were given one of two doses or a dummy injection once a week for about eight months. The lower dose group lost 10.1% of body weight and the higher dose group 12.6%. The dummy group gained...

     New England Journal of Medicine, 2025 · 610 people

   • Mazdutide produced large weight loss at its highest dose, and made a lot of people vomit. 461 adults at 27 Chinese hospitals got the weekly shot or a dummy one for 60 weeks, two to one. Nobody involved knew which. The drug group lost 16.65% of their body weight against 1.50% on the dummy, and 84.3% lost at least a...

     JAMA, 2026 · 461 people

9. 09CagrilintidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 5,752 people given it.7 reported

   2,004 people3 studies

   • In a large late-stage trial the pair took off substantial weight and pulled most people's blood sugar into range. 1,206 adults with extra weight and type 2 diabetes took CagriSema or a dummy injection for about sixteen months. Body weight fell 13.7% on the drug and 3.4% on the dummy. Nearly three quarters got their...

     New England Journal of Medicine, 2025 · 1,206 people

   • Cagrilintide on its own took off weight, and its top dose edged out an approved drug. 706 adults carrying extra weight took cagrilintide at one of several doses, a dummy injection, or liraglutide, for six months. Weight fell between 6.0% and 10.8% depending on dose, against 3.0% on the dummy. At 4.5 mg it beat...

     The Lancet, 2021 · 706 people

   • Adding cagrilintide to semaglutide roughly doubled weight loss in a small early trial. 92 adults with type 2 diabetes took the pair, or semaglutide alone, or cagrilintide alone, for eight months. The pair took off 15.6% of body weight. Semaglutide alone took off 5.1% and cagrilintide alone 8.1%. This was an early...

     The Lancet, 2023 · 92 people

10. 10SurvodutidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 2,034 people given it.7 reported

    1,741 people4 studies

    • Survodutide produced substantial weight loss in a large trial built to modern standards. It gave 725 adults with obesity and no diabetes a weekly injection at one of two doses, or a dummy injection, for about eighteen months. People on the drug lost around an eighth of their body weight. People on the dummy injection...

      New England Journal of Medicine, 2026 · 725 people

    • Against semaglutide, survodutide matched it on blood sugar, beat it on weight, and cost more in side effects. The trial put 413 people with type 2 diabetes on one of six survodutide doses, on semaglutide, or on a dummy injection for four months. Average blood sugar fell by about the same amount on both drugs. Weight...

      Diabetologia, 2024 · 413 people

    • Survodutide produced large weight loss in people without diabetes. Three hundred and eighty-seven adults were treated for about eleven months, at several doses or with a dummy injection. At the highest dose people lost about 14.9% of their body weight. On the dummy they lost 2.8%. For someone of 100 kg that is roughly...

      The Lancet Diabetes and Endocrinology, 2024 · 387 people

11. 11RetatrutidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 5 completed trials, 1,345 people given it.8 reported

    1,156 people3 studies

    • This is the first full late-stage report for retatrutide, and it holds up. 537 people with type 2 diabetes not controlled by diet and exercise took the drug or a dummy shot for 40 weeks. Nobody involved knew which. Average blood sugar over three months fell between 1.69 and 1.94 points across the doses, against 0.81...

      The Lancet, 2026 · 537 people

    • It worked, and this is still an early trial. 338 adults with obesity took retatrutide or a dummy injection every week for about eleven months. The dummy group finished about 2% lighter. On the strongest dose people finished about 24% lighter, with smaller losses on smaller doses. This was a middle stage trial, built...

      New England Journal of Medicine, 2023 · 338 people

    • Retatrutide lowered blood sugar and weight more than an older drug, in a mid-stage trial. 281 people with type 2 diabetes were split by chance between retatrutide, dulaglutide and a dummy shot, and nobody involved knew which. At the top dose, average blood sugar over three months fell about 2 points, against almost...

      The Lancet, 2023 · 281 people

12. 12CotadutidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 6 completed trials, 1,221 people given it.

    899 people3 studies1 found nothing

    • Cotadutide lowered blood sugar and weight in people with diabetes, and it beat liraglutide on weight at the top dose. 834 adults on metformin were split by chance across three doses, a dummy, or liraglutide, for about a year. Blood sugar and weight both fell against the dummy. At the highest dose, liver enzymes and...

      Diabetes Care, 2021 · 834 people

    • An early trial showed cotadutide blunts the blood sugar spike after a meal, and takes off some weight. 65 adults with diabetes and extra weight took it daily for seven weeks, or a dummy. After meals, blood sugar rose about a fifth less, while it climbed on the dummy. Weight fell about three and a half percent, against...

      Journal of Clinical Endocrinology and Metabolism, 2020 · 65 people

    • found nothingPeople lost weight on cotadutide because they ate less, not because they burned more. This small study followed 12 people on the drug and 7 on a dummy for six weeks. The drug group lost four percent of their body weight against one and a half percent on the dummy. They ate far less food. Energy burned, measured...

      Diabetes, Obesity and Metabolism, 2024 · number of people not given

13. 13PramlintidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 684 people given it.

    684 people2 studies

    • Pramlintide improved blood sugar control in type 1 diabetes, and people lost weight instead of gaining it. Four hundred and eighty patients were treated alongside their insulin for a year. At three months, average blood sugar had fallen by 0.67 percentage points on the drug and 0.16 on a dummy injection. Severe low...

      Diabetes Care, 2002 · 480 people

    • In people with obesity but no diabetes, pramlintide produced a small amount of weight loss. Two hundred and four of them took it or a dummy injection for four months, with the dose built up slowly. The drug group ended 3.6 kg lighter than the dummy group, about 3.7% of body weight. That is far less than newer weight...

      Journal of Clinical Endocrinology and Metabolism, 2007 · 204 people

14. 14EcnoglutidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 664 people given it.1 reported

    664 people2 studies

    • It worked, in a full sized trial. 664 Chinese adults lost between 9 and 13 percent of their body weight over 40 weeks, depending on the dose, while the dummy group lost essentially nothing. Nearly nine in ten on the top dose lost at least 5 percent. One thing to hold in mind. Everyone in this trial was Chinese, so...

      The Lancet Diabetes and Endocrinology, 2025 · 664 people

    • China's regulator approved it for weight management in March 2026. The company reports an average weight loss of about 15 percent after 48 weeks on the top dose, nearly all of it over and above what the dummy group lost. An approval is a real milestone. It is also specific to one country, and it is not the same thing...

      Sciwind Biosciences press release, 2026 · number of people not given

15. 15BimagrumabBiologicModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 507 people given it.1 reported

    507 people1 study

    • Added to semaglutide, it took off more weight than semaglutide managed alone. 507 adults were treated for nearly a year. The high dose combination lost about 17.8 kg, semaglutide on its own about 14.2 kg, the muscle drug on its own about 9.3 kg, and the dummy group about 3.3 kg. In pounds that is roughly 39, 31, 20...

      Nature Medicine, 2026 · 507 people

16. 16NNC0480-0389PeptideModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 500 people given it.2 reported

    500 people1 study

    • This trial has finished, and the registry now carries its numbers. Novo Nordisk enrolled 500 people with type 2 diabetes and completed it in March 2023. Weight fell 9.8 kg on semaglutide with a dummy added, and between 8.9 and 12.0 kg across the doses with the GIP drug on top. The GIP drug by itself gave 4.7 kg, and a...

      ClinicalTrials.gov, 2026 · 500 people

17. 17PetrelintidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 1 completed trial, 493 people given it.2 reported

    493 people2 studies

    • It works, and it works less well than the drugs it is chasing. 493 people took part, and the company reports up to about 11 percent average weight loss after 42 weeks, against under 2 percent on a dummy. This is a press release, so no outside reviewer has been through the detail yet. A larger trial is meant to start...

      Zealand Pharma press release, 2026 · 493 people

    • The earliest human studies went smoothly and showed weight coming off. Side effects were mostly mild stomach trouble. The purpose of trials at this stage is to find out whether people can take a drug at all, and at what dose. This one passed that test, which is why it went forward. It is not evidence that the drug...

      Diabetes, Obesity and Metabolism, 2026 · number of people not given

18. 18BeinaglutidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 443 people given it.

    741 people2 studies

    • Three shots a day for 16 weeks took off a modest amount of weight, and half the people felt sick. 427 Chinese adults without diabetes were split by chance to 0.2 mg under the skin three times daily or a dummy, and nobody knew which. Weight fell 6.0 percent against 2.4 percent on the dummy. Nausea hit 49.3 percent...

      Diabetes, Obesity and Metabolism, 2024 · 427 people

    • Nobody was given anything here. Researchers looked back at the records of 314 Chinese patients with type 2 diabetes. After three months, the records showed weight down 10.05 kg and average blood sugar down 2.87 points. Those numbers are far bigger than the careful study with a dummy-shot group found. Looking back only...

      Obesity Science and Practice, 2019 · 314 people

19. 19BofanglutidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 5 completed trials, 750 people given it.4 reported

    386 people2 studies

    • It took off serious weight in overweight Chinese adults, and almost everyone had side effects. 340 adults averaging 95.6 kg were split by chance across five doses or a dummy, and nobody knew which. Over 30 weeks weight fell between 9.75 and 16.69 percent on the drug, against 1.15 percent on the dummy. Side effects hit...

      Signal Transduction and Targeted Therapy, 2026 · 340 people

    • This was a small early study to find the right dose. It does not tell you how well the drug works. Sixty people signed up and 46 finished. In the second part, weight fell 17.8 percent on weekly shots and 12.8 percent on shots every two weeks, against 0.7 percent on a dummy shot. The first part moved the same way, by...

      Cell Reports Medicine, 2026 · 46 people

20. 20ExenatidePeptideStrong. At least two finished studies in people, and at least 1,000 people who took it. 2 completed trials, 15,088 people given it.1 reported

    336 people1 study

    • Exenatide lowered blood sugar and took off a little weight in people already on metformin. 336 patients at 82 US clinics added exenatide or a dummy injection twice a day for seven months. Average blood sugar over three months fell about three quarters of a point on the higher dose and four tenths on the lower one. On...

      Diabetes Care, 2005 · 336 people

21. 21VisepegenatidePeptideModerate. At least one finished study in people, and at least 100 people who took it. 4 completed trials, 572 people given it.

    273 people1 study

    • It lowered blood sugar in people newly treated for diabetes, and the weight number needs care. 273 adults who had never been treated were split evenly by chance to 150 micrograms weekly or a dummy for 24 weeks. Average blood sugar fell 1.36 points against 0.63. 50.4 percent got below 7.0 percent against 14.2 percent....

      The Lancet Regional Health Western Pacific, 2024 · 273 people

22. 22HRS-7535Small moleculeModerate. At least one finished study in people, and at least 100 people who took it. 2 completed trials, 235 people given it.2 reported

    235 people2 studies

    • The pill worked in its first real test in people with obesity. 235 adults in China took one of four doses or a dummy pill. After half a year the top dose took off about 9 percent of body weight, against about 2.5 percent on the dummy. Nausea and other stomach upsets were the most common complaint and were mostly mild....

      Nature Communications, 2026 · 235 people

    • Two large final-stage trials both came out positive. Over about a year, people taking the daily pill lost roughly 11% of their body weight, against a little over 2% on a dummy pill. In the separate diabetes trial, average blood sugar over three months fell by 1.5 to 1.7 percentage points. Both results arrived as a...

      Kailera press release, 2026 · number of people not given

23. 23ResveratrolSupplementModerate. At least one finished study in people, and at least 100 people who took it. 14 completed trials, 403 people given it.7 reported

    192 people1 study1 found nothing

    • found nothingThe longest and largest diabetes trial of resveratrol found nothing that counted. 192 patients took 40 mg, 500 mg or a dummy pill every day for six months. An inflammation marker fell further on resveratrol, but not by enough to call real. Weight, waist, blood pressure, blood sugar, insulin and a string of other...

      Pharmacological Research, 2016 · 192 people

24. 24SupaglutideBiologicModerate. At least one finished study in people, and at least 100 people who took it. 3 completed trials, 190 people given it.

    190 people2 studies

    • It lowered blood sugar well in newly diagnosed diabetes, and barely touched weight at the lower dose. A first stage split 140 people across three doses and a dummy. A second stage split 297 more to 1 mg, 3 mg or a dummy. At week 24 average blood sugar fell 1.73 points on 1 mg and 2.15 on 3 mg, ahead of the dummy by...

      Diabetologia, 2026 · 140 people

    • The entire published obesity record for this drug is fifty people. They were spread across five doses and a dummy, starting at an average weight of 92.9 kg. Weight fell 7.16 percent against 0.86 percent on the dummy, and 82.5 percent of treated people lost at least a twentieth of their body weight, against nobody on...

      Diabetes, Obesity and Metabolism, 2026 · 50 people